Cell Source Valuation
| CLCS Stock | USD 0.29 0.02 6.45% |
Cell Source seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Cell Source from analyzing the firm fundamentals such as Price To Earning of (3.28) X, shares outstanding of 35.25 M, and Return On Asset of -3.78 as well as examining its technical indicators and probability of bankruptcy. . In general, most investors favor acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Overvalued
Today
Please note that Cell Source's price fluctuation is out of control at this time. Calculation of the real value of Cell Source is based on 3 months time horizon. Increasing Cell Source's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cell otc stock is determined by what a typical buyer is willing to pay for full or partial control of Cell Source. Since Cell Source is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cell OTC Stock. However, Cell Source's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.29 | Real 0.28 | Hype 0.29 | Naive 0.28 |
The intrinsic value of Cell Source's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cell Source's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cell Source helps investors to forecast how Cell otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cell Source more accurately as focusing exclusively on Cell Source's fundamentals will not take into account other important factors: Cell Source Total Value Analysis
Cell Source is currently forecasted to have valuation of 59.65 M with market capitalization of 10.61 M, debt of 6.5 M, and cash on hands of 93.09 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cell Source fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
59.65 M | 10.61 M | 6.5 M | 93.09 K |
Cell Source Asset Utilization
One of the ways to look at asset utilization of Cell is to check how much profit was generated for every dollar of assets it reports. Cell Source shows a negative utilization of assets of -3.78 percent, losing $0.0378 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Cell Source shows how discouraging it operates for each dollar spent on its assets.Cell Source Ownership Allocation
Cell Source holds a total of 35.25 Million outstanding shares. Cell Source retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cell Source Profitability Analysis
Net Loss for the year was (5.47 M) with profit before overhead, payroll, taxes, and interest of 0.About Cell Source Valuation
The otc valuation mechanism determines Cell Source's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Cell Source based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cell Source. We calculate exposure to Cell Source's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cell Source's related companies.Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.
8 Steps to conduct Cell Source's Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Cell Source's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Cell Source's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Cell Source's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Cell Source's revenue streams: Identify Cell Source's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Cell Source's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Cell Source's growth potential: Evaluate Cell Source's management, business model, and growth potential.
- Determine Cell Source's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Cell Source's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Cell Source Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cell Source does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 29.1 M | |
| Retained Earnings | -31.2 M | |
| Shares Float | 24.5 M |
Additional Tools for Cell OTC Stock Analysis
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.